Angiogenesis in peritoneal dialysis

Kidney and Blood Pressure Research

Volumn 34, Issue 4, 2011, Pages 245-252

  Stavenuiter, A W D ^a   Schilte, M N ^a   Ter Wee, P M ^a   Beelen, R H J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Peritoneal dialysis; Ultrafiltration capacity

Indexed keywords

PERITONEAL DIALYSIS FLUID; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; CELL TYPE; CONFERENCE PAPER; HUMAN; INFLAMMATION; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PERITONEUM CELL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEUM; PYRROLES; RATS;

EID: 79959518289     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000326953     Document Type: Conference Paper

References (59)

1. Palmer RA: As it was in the beginning: a his-tory of peritoneal dialysis. Perit Dial Int 1982; 2:16-22.
2. Rippe B, Rosengren BI, Venturoli D: The peritoneal microcirculation in peritoneal di-alysis. Microcirculation 2001; 8: 303-320.
3. Krediet RT, Lindholm B, Rippe B: Patho-physiology of peritoneal membrane failure. Perit Dial Int 2000; 20(suppl 4):S22-S42
4. ERA-EDTA. ERA-EDTA Registry Annual Report 2008. 2010. Ref Type: Report.
5. Williams JD, Craig KJ, Topley N, Von Ruh-land C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with re-nal disease. J Am Soc Nephrol 2002; 13: 470-479. (Pubitemid 34106290)
6. Digenis GE: Anatomy of the Peritoneal Membrane. Perit Dial Bull 1984; 4:63-69. (Pubitemid 14056964)
7. Nagy JA: Peritoneal membrane morphology and function. Kidney Int 1996; 50:S2-S11. (Pubitemid 26356891)
8. Nessim SJ, Perl J, Bargman JM: The renin-angiotensin-aldosterone system in peritone-al dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int 2010; 78: 23-28.
9. Michels WM, Zweers MM, Smit W, Korevaar J, Struijk DG, van Westrhenen R, Krediet RT: Does lymphatic absorption change with the duration of peritoneal dialysis? Perit Dial Int 2004; 24: 347-352. (Pubitemid 39206629)
10. Lai KN, Tang SC, Leung JC: Mediators of in-flammation and fibrosis. Perit Dial Int 2007; 27(suppl 2):S65-S71.
11. Zareie M, van Lambalgen A A, De Vriese AS, Van Gelderop E, Lameire N, ter Wee PM, Beelen RH, van den Born J, Tangelder GJ: Increased leukocyte rolling in newly formed mesenteric vessels in the rat during perito-neal dialysis. Perit Dial Int 2002; 22:655-662. (Pubitemid 36131494)
12. Hekking LH, Aalders MC, van Gelderop E, Zweers MM, Struijk DG, Havenith CE, Beel-en RH: Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis. Adv Perit Dial 1998; 14:14-18.
13. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, Leyssens A, Schalkwijk CG, Beelen RH, ter Wee PM, van den Born J: Contribu-tion of lactate buffer, glucose and glucose deg-radation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-2637. (Pubitemid 37483799)
14. Calame W, Hendrickx RJBM, Namavar F, Oe LP, Beelen RHJ: Effect of glucose in dialysis fluid on antibacterial defense in the perito-neal cavity. Infect 1995; 30:227-233.
15. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de G, I, Schadee-Eestermans IL, Havenith CE, van den Born J, ter Wee PM, Beelen RH: Better preservation of peri-toneal morphologic features and defense in rats after long-term exposure to a bicar-bonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12: 2775-2786. (Pubitemid 33115426)
16. Mortier S, Faict D, Lameire NH, De Vriese AS: Benefits of switching from a convention-al to a low-GDP bicarbonate/lactate-buff-ered dialysis solution in a rat model. Kidney Int 2005; 67:1559-1565. (Pubitemid 40463136)
17. Honda K, Nitta K, Horita S, Yumura W, Ni-hei H, Nagai R, Ikeda K, Horiuchi S: Accu-mulation of advanced glycation end prod-ucts in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-1549. (Pubitemid 29241752)
18. Yamagishi S, Yonekura H, Yamamoto Y, Kat-suno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H: Ad-vanced glycation end products-driven an-giogenesis in vitro. J Biol Chem 1997; 272: 8723-8730.
19. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH: Inhibition of the interac-tion of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal mem-brane. J Am Soc Nephrol 2003; 14: 2109-2118. (Pubitemid 36909919)
20. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glyco-sylation induces transendothelial human monocyte chemotaxis and secretion of plate-let-derived growth-factor-role in vascular-disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87: 9010-9014. (Pubitemid 120007639)
21. Zweers MM, Struijk DG, Smit W, Krediet RT: Vascular endothelial growth factor in perito-neal dialysis: a longitudinal follow-up. J Lab Clin Med 2001; 137:125-132. (Pubitemid 32116955)
22. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
23. Yuan JZ, Fang W, Ni ZH, Dai HL, Lin AW, Cao LO, Qian JQ: Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2. Pediatr Nephrol 2009; 24: 163-170.
24. Loureiro J, Schilte M, Aguilera A, Albar-Viz-caino P, Ramirez-Huesca M, Perez-Lozano ML, Gonzalez-Mateo G, Aroeira LS, Selgas R, Mendoza L, Ortiz A, Ruiz-Ortega M, van den BJ, Beelen RH, Lopez-Cabrera M: BMP-7 blocks mesenchymal conversion of meso-thelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol Dial Transplant 2010; 25:1098-1108.
25. Bos HJ, van Bronswijk H, Helmerhorst TJ, Oe PL, Hoefsmit EC, Beelen RH: Distinct sub-populations of elicited human macrophages in peritoneal dialysis patients and women undergoing laparoscopy: a study on peroxi-datic activity. J Leukoc Biol 1988; 43:172-178. (Pubitemid 18062546)
26. Kamiyama M, Pozzi A, Yang L, Debusk LM, Breyer RM, Lin PC: EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006; 25: 7019-7028. (Pubitemid 44722070)
27. Niu J, Azfer A, Zhelyabovska O, Fatma S, Ko-lattukudy PE: Monocyte chemotactic pro-tein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 2008; 283: 14542-14551.
28. Margetts PJ, Kolb M, Yu L, Hoff CM, Hol-mes CJ, Anthony DC, Gauldie J: Inflamma-tory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-2294. (Pubitemid 34663419)
29. Rosell A, Arai K, Lok J, He TR, Guo SZ, Na-varro M, Montaner J, Katusic ZS, Lo EH: In-terleukin-1 beta augments angiogenic re-sponses of murine endothelial progenitor cells in vitro. J Cereb Blood Flow Metab 2009; 29: 933-943.
30. Fan F, Stoeltzing O, Liu WB, McCarty MF, Jung YD, Reinmuth N, Ellis LM: Interleu-kin-1 beta regulates angiopoietin-1 expres-sion in human endothelial cells. Cancer Res 2004; 64:3186-3190. (Pubitemid 38581421)
31. Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y Zhu W, Chen Y Lawton MT, Young WL, Yang GY: Interleukin-6 stimulates circulat-ing blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28:90-98.
32. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metallo-proteinases production and regulated angio-genesis. J Immunol 2003; 170:3369-3376. (Pubitemid 36302216)
33. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N: Macro-phage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329:630-632. (Pubitemid 17140112)
34. Jimenez-Heffernan JA, Bajo MA, Perna C, Del PG, Larrubia JR, Gamallo C, Sanchez-Tomero JA, Lopez-Cabrera M, Selgas R: Mast cell quantification in normal perito-neum and during peritoneal dialysis treatment. Arch Pathol Lab Med 2006; 130:1188-1192. (Pubitemid 44168789)
35. Alscher DM, Braun N, Biegger D, Fritz P: Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peri-toneal sclerosis patients. Am J Kidney Dis 2007; 49:452-461.
36. Norrby K: Mast cells and angiogenesis. AP-MIS 2002; 110: 355-371.
37. Katsanos GS, Anogeianaki A, Orso C, Tete S, Salini V, Antinolfi PL, Sabatino G: Mast cells and chemokines. J Biol Regul Homeost Agents 2008; 22:145-152.
38. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL: Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angio-genic factor. J Clin Invest 1997; 99: 2691-2700. (Pubitemid 27259816)
39. Muramatsu M, Katada J, Hayashi I, Majima M: Chymase as a proangiogenic factor. A possible involvement of chymase-angioten-sin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000; 275:5545-5552. (Pubitemid 30115190)
40. Zareie M, Hekking LH, Driesprong BA, ter Wee PM, Beelen RH, van den Born J: Accu-mulation of omental mast cells during peri-toneal dialysis. Perit Dial Int 2001; 21(suppl 3):S373-S376.
41. Zareie M, Fabbrini P, Hekking LH, Keuning ED, ter Wee PM, Beelen RH, van den Born J: Novel role for mast cells in omental tissue re-modeling and cell recruitment in experi-mental peritoneal dialysis. J Am Soc Nephrol 2006; 17:3447-3457. (Pubitemid 44865287)
42. Riese J, Niedobitek G, Lisner R, Jung A, Ho-henberger W, Haupt W: Expression of inter-leukin-6 and monocyte chemoattractant protein-1 by peritoneal sub-mesothelial cells during abdominal operations. J Pathol 2004; 202: 34-40. (Pubitemid 38072843)
43. Hekking LH, Zweers MM, Keuning ED, Driesprong BA, de Waart DR, Beelen RH, van den Born J: Apparent successful meso-thelial cell transplantation hampered by peritoneal activation. Kidney Int 2005; 68: 2362-2367. (Pubitemid 43117816)
44. El-Assal ON, Paddock H, Marquez A, Besner GE: Heparin-binding epidermal growth fac-tor-like growth factor gene disruption is as-sociated with delayed intestinal restitution, impaired angiogenesis and poor survival after intestinal ischemia in mice. J Pediatr Surg 2008; 43:1182-1190. (Pubitemid 351818222)
45. Cross MJ, Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling path-ways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-207. (Pubitemid 32244307)
46. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ: Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases. Br J Cancer 2000; 82: 1233-1238. (Pubitemid 30128884)
47. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, de Strihou CV, Kuro-kawa K: Glucose degradation product meth-ylglyoxal enhances the production of vascu-lar endothelial growth factor in peritoneal cells: role in the functional and morphologi-cal alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260-264. (Pubitemid 30001930)
48. Visser CE, Tekstra J, Brouwer-Steenbergen JJ, Tuk CW, Boorsma DM, Sampat-Sardjoep-ersad SC, Meijer S, Krediet RT, Beelen RH: Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol 1998; 112: 270-275. (Pubitemid 28266686)
49. Pecoits-Filho R, Araujo MRT, Lindholm B, Stenvinkel P, Abensur H, Romao JE, Mar-condes M, de Oliveira AHF, Noronha IL: Plasma and dialysate IL-6 and VEGF con-centrations are associated with high perito-neal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-1486.
50. Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, Bajo MA, Del PG, Sanchez-Tomero JA, Ji-menez-Heffernan JA, Lopez-Cabrera M: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46: 938-948. (Pubitemid 41505470)
51. Duman S: The renin-angiotensin system and peritoneal dialysis. Perit Dial Int 2004; 24: 5-9. (Pubitemid 38886090)
52. Aroeira LS, Lara-Pezzi E, Loureiro J, Agui-lera A, Ramirez-Huesca M, Gonzalez-Mateo G, Perez-Lozano ML, bar-Vizcaino P, Bajo MA, Del PG, Sanchez-Tomero JA, Jimenez-Heffernan JA, Selgas R, Lopez-Cabrera M: Cyclooxygenase-2 mediates dialysate-in-duced alterations of the peritoneal mem-brane. J Am Soc Nephrol 2009; 20:582-592.
53. Iniguez MA, Rodriguez A, Volpert OV, Fres-no M, Redondo JM: Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9: 73-78. (Pubitemid 36313868)
54. Fabbrini P, Schilte MN, Zareie M, ter Wee PM, Keuning ED, Beelen RH, van den BJ: Ce-lecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltra-tion failure in experimental peritoneal dialy-sis. Nephrol Dial Transplant 2009; 24:3669-3676.
55. Tapiawala SN, Bargman JM, Oreopoulos DG, Simons M: Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis pa-tient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates. Int Urol Nephrol 2009; 41: 431-434.
56. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D Rini BI, Michaelson MD, Motzer RJ: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcino-ma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5:32.
57. Sandoval P, Loureiro J, Gonzalez-Mateo G, Perez-Lozano ML, Maldonado-Rodriguez A, Sanchez-Tomero JA, Mendoza L, Sant-amaria B, Ortiz A, Ruiz-Ortega M, Selgas R Martin P, Sanchez-Madrid F, Aguilera A, Lo-pez-Cabrera M: PPAR-gamma agonist rosi-glitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest 2010; 90:1517-1532.
58. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosigli-tazone-A meta-analysis. JAMA2007; 298: 1189-1195. (Pubitemid 47403105)
59. Schilte MN, Celie JW, Wee PM, Beelen RH, van den Born J: Factors contributing to peri-toneal tissue remodeling in peritoneal dialy-sis. Perit Dial Int 2009; 29:605-617.